Bullish
LBRX: LB-102 demonstrates rapid efficacy and strong safety in late-stage trials for major neuropsychiatric disorders
LB-102, a novel derivative of amisulpride from LBRX, is showing promising results in late-stage trials for schizophrenia, bipolar depression, and adju...